Skip to main content

Table 1 Clinico-pathological profile and the KIBRA expression of the study cohort

From: KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy

Clinico-pathological features n % Clinico-pathological features n %
Histological type Lympho-vascular invasion
 Invasive duct (NOS) 1081 96.3  Presence 452 43.2
 Invasive lobular 17 1.5  Absence 595 56.8
 Mucinous 4 0.4  Unknown 77  
 Other types 20 1.8  
 Unknown 2   Expression of ER
Age at presentation  Positive 525 46.7
  < =35 years 74 6.6  Negative 598 53.3
 36–60 years 729 65.1  Unknown 1  
  > 60 years 317 28.3 Expression of PgR
 Unknown 4    Positive 513 46.0
Tumour size  Negative 602 54.0
  < 20 mm 376 33.8  Unknown 9  
  > 20-50 mm 637 57.2 Expression of HER2
  > 50 mm 101 9.0  Positive 219 21.0
 Unknown 10    Negative 823 79.0
Nottingham grade  Borderline 72  
 Grade 1 141 13.5  Unknown 10  
 Grade 2 505 48.4 Molecular classification
 Grade 3 398 38.1  luminal A 278 26.8
 Unknown 80    luminal B (Her2 negative) 126 12.2
Lymph node stage  luminal B (Her2 positive) 66 6.4
 Stage 0 543 48.4  Her2-enriched 153 14.8
 Stage 1 274 24.4  TNBC 329 31.8
 Stage 2 182 16.2  Basal-like 84 8.1
 Stage 3 123 11  
 Unknown 2   
TNM stage KIBRA expression
 I 165 16.0  Cytoplasm + nuclei 234 25.7
 II 478 46.5  Only cytoplasm 125 13.7
 III 377 36.7  Only nuclei 173 19.0
 IV 8 0.8  Overall KIBRA-Low 377 41.5
 Unknown 96    Unknown 215  
  1. n number, % percentage, NOS not otherwise specified, TNM tumour-node-metastasis, ER estrogen receptors, PgR progesterone receptors, HER2 human epidermal growth factor receptor2